Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Stage 4 Chronic Kidney Disease
ChiCTR2100044600Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Plasma concentration of dapagliflozin and Plasma concentration of dapagliflozin-3-O-glucuronide (D3OG). Started Apr 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100044600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044600.